Sweden · Delayed Price · Currency is SEK Hansa Biopharma AB Statistics
Total Valuation
STO:HNSA has a market cap or net worth of SEK 3.12 billion. The enterprise value is 3.61 billion.
| Market Cap | 3.12B |
| Enterprise Value | 3.61B |
Important Dates
The last earnings date was Wednesday, July 22, 2026.
| Earnings Date | Jul 22, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:HNSA has 101.76 million shares outstanding. The number of shares has increased by 42.70% in one year.
| Current Share Class | 101.76M |
| Shares Outstanding | 101.76M |
| Shares Change (YoY) | +42.70% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.12% |
| Owned by Institutions (%) | 22.76% |
| Float | 72.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 5.53 |
| PS Ratio | 16.49 |
| PB Ratio | -6.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 19.03 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.25
| Current Ratio | 1.25 |
| Quick Ratio | 1.23 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.86 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -37.83% |
| Return on Invested Capital (ROIC) | -73.76% |
| Return on Capital Employed (ROCE) | -114.13% |
| Weighted Average Cost of Capital (WACC) | 12.05% |
| Revenue Per Employee | 1.45M |
| Profits Per Employee | -5.76M |
| Employee Count | 122 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 14.88 |
Taxes
In the past 12 months, STO:HNSA has paid 2.22 million in taxes.
| Income Tax | 2.22M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.72% in the last 52 weeks. The beta is 1.59, so STO:HNSA's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +56.72% |
| 50-Day Moving Average | 33.20 |
| 200-Day Moving Average | 32.38 |
| Relative Strength Index (RSI) | 71.31 |
| Average Volume (20 Days) | 500,286 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:HNSA had revenue of SEK 189.46 million and -755.14 million in losses. Loss per share was -7.74.
| Revenue | 189.46M |
| Gross Profit | 108.32M |
| Operating Income | -577.53M |
| Pretax Income | -752.93M |
| Net Income | -755.14M |
| EBITDA | -589.36M |
| EBIT | -589.36M |
| Loss Per Share | -7.74 |
Balance Sheet
The company has 552.81 million in cash and 1.03 billion in debt, with a net cash position of -480.99 million or -4.73 per share.
| Cash & Cash Equivalents | 552.81M |
| Total Debt | 1.03B |
| Net Cash | -480.99M |
| Net Cash Per Share | -4.73 |
| Equity (Book Value) | -520.24M |
| Book Value Per Share | -5.11 |
| Working Capital | 136.55M |
Cash Flow
| Operating Cash Flow | -569.63M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 7.16M |
| Net Borrowing | 115.72M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 57.17% |
| Operating Margin | -304.83% |
| Pretax Margin | -397.41% |
| Profit Margin | n/a |
| EBITDA Margin | -311.07% |
| EBIT Margin | -311.07% |
| FCF Margin | n/a |
Dividends & Yields
STO:HNSA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -42.70% |
| Shareholder Yield | -42.70% |
| Earnings Yield | -24.17% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for STO:HNSA is 73.00, which is 79.98% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 73.00 |
| Price Target Difference | 79.98% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 58.73% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |